Update: 07.02.2021
Last week: 4 week 2022 (24.01.2022 - 30.01.2022)
Last full month: Dec 2021
| Time period | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | ||||||||
| WoW | 2 685 | 8.1% | 51.1% | -3 | 1 178 858 | 8.4% | 79.8% | -1.8 |
| MoM | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| YTD | 9 230 | 7.4% | 52.0% | -5.8 | 4 050 246 | 37.3% | 80.2% | -0.3 |
| MAT | 118 241 | -22.8% | 55.1% | -6.4 | 46 711 892 | 1.9% | 80.2% | -0.6 |
| CAPSICAM | ||||||||
| WoW | 23 941 | -0.1% | 3.4% | 0 | 9 777 858 | -0.6% | 3.6% | -0.1 |
| MoM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| YTD | 89 112 | -7.2% | 3.5% | 0.1 | 36 547 804 | -10.0% | 3.8% | -0.3 |
| MAT | 1 058 172 | -19.7% | 3.2% | -0.2 | 434 873 452 | -9.1% | 3.5% | -0.2 |
| MILDRONATE | ||||||||
| WoW | 109 667 | 1.8% | 20.7% | -0.8 | 45 878 399 | 4.2% | 18.1% | -0.7 |
| MoM | 417 135 | -7.8% | 22.5% | 0.6 | 162 253 267 | -6.5% | 19.0% | 0.2 |
| YTD | 392 474 | 9.4% | 16.6% | 0.7 | 159 449 854 | 2.3% | 14.8% | -0.5 |
| MAT | 4 829 519 | 10.2% | 17.3% | 2.9 | 1 937 162 825 | 13.2% | 15.4% | 2.2 |
| SULFARGIN | ||||||||
| WoW | 3 310 | -2.7% | 0.9% | 0 | 1 611 287 | -2.9% | 1.3% | -0.1 |
| MoM | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| YTD | 12 380 | -1.3% | 0.9% | 0.1 | 6 069 031 | 4.3% | 1.3% | 0.2 |
| MAT | 163 985 | -21.7% | 0.8% | -0.1 | 80 012 278 | -9.2% | 1.2% | -0.1 |
| VIPROSAL | ||||||||
| WoW | 30 926 | 6.7% | 4.4% | 0.2 | 12 164 400 | 6.8% | 4.5% | 0.2 |
| MoM | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| YTD | 110 013 | 27.9% | 4.3% | 1.2 | 43 300 005 | 29.5% | 4.5% | 1.1 |
| MAT | 1 267 532 | -10.0% | 3.8% | 0.2 | 481 150 548 | -1.6% | 3.9% | 0.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 2 685 | 8.1% | 51.1% | -3 | 1 178 858 | 8.4% | 79.8% | -1.8 |
| CAPSICAM | 23 941 | -0.1% | 3.4% | 0 | 9 777 858 | -0.6% | 3.6% | -0.1 |
| MILDRONATE | 109 667 | 1.8% | 20.7% | -0.8 | 45 878 399 | 4.2% | 18.1% | -0.7 |
| SULFARGIN | 3 310 | -2.7% | 0.9% | 0 | 1 611 287 | -2.9% | 1.3% | -0.1 |
| VIPROSAL | 30 926 | 6.7% | 4.4% | 0.2 | 12 164 400 | 6.8% | 4.5% | 0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 7 842 | -1.5% | 45.8% | -1.3 | 3 429 269 | -1.2% | 75.8% | -0.8 |
| CAPSICAM | 106 383 | 11.1% | 4.0% | 0.5 | 43 240 220 | 11.8% | 4.3% | 0.6 |
| MILDRONATE | 417 135 | -7.8% | 22.5% | 0.6 | 162 253 267 | -6.5% | 19.0% | 0.2 |
| SULFARGIN | 17 478 | 36.4% | 1.2% | 0.3 | 8 443 597 | 31.0% | 1.7% | 0.4 |
| VIPROSAL | 137 425 | -3.2% | 5.2% | 0 | 54 451 164 | -0.3% | 5.5% | 0.2 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 9 230 | 7.4% | 52.0% | -5.8 | 4 050 246 | 37.3% | 80.2% | -0.3 |
| CAPSICAM | 89 112 | -7.2% | 3.5% | 0.1 | 36 547 804 | -10.0% | 3.8% | -0.3 |
| MILDRONATE | 392 474 | 9.4% | 16.6% | 0.7 | 159 449 854 | 2.3% | 14.8% | -0.5 |
| SULFARGIN | 12 380 | -1.3% | 0.9% | 0.1 | 6 069 031 | 4.3% | 1.3% | 0.2 |
| VIPROSAL | 110 013 | 27.9% | 4.3% | 1.2 | 43 300 005 | 29.5% | 4.5% | 1.1 |
| Brand | Volume | Change, % | MS Volume | Change, p.p. | Value, rur | Change, % | MS Value | Change, p.p. |
|---|---|---|---|---|---|---|---|---|
| APILAC | 118 241 | -22.8% | 55.1% | -6.4 | 46 711 892 | 1.9% | 80.2% | -0.6 |
| CAPSICAM | 1 058 172 | -19.7% | 3.2% | -0.2 | 434 873 452 | -9.1% | 3.5% | -0.2 |
| MILDRONATE | 4 829 519 | 10.2% | 17.3% | 2.9 | 1 937 162 825 | 13.2% | 15.4% | 2.2 |
| SULFARGIN | 163 985 | -21.7% | 0.8% | -0.1 | 80 012 278 | -9.2% | 1.2% | -0.1 |
| VIPROSAL | 1 267 532 | -10.0% | 3.8% | 0.2 | 481 150 548 | -1.6% | 3.9% | 0.1 |
## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "VIPROSAL"## [1] "VIPROSAL B UNGUENT FOR EXT USE 30 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 50 G #1"## [1] "VIPROSAL B UNGUENT FOR EXT USE 75 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "CAPSICAM"## [1] "CAPSICAM UNGUENT FOR EXT USE 30 G #1"## [1] "CAPSICAM UNGUENT FOR EXT USE 50 G #1"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "MILDRONATE"## [1] "MILDRONATE CAPS 250 MG #40"## [1] "MILDRONATE CAPS 500 MG #60"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "SULFARGIN"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 15 G #1"## [1] "SULFARGIN UNGUENT FOR EXT USE 1% 50 G #1"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"## [1] "APILAC"## [1] "APILAC TABS 10 MG #25"## [1] "APILAC TABS 10 MG #50"Abbreviations
WoW - Week Over Week Change = Sales of the last week / Sales of the previous week - 1
MoM - Month Over Month Change = Sales of the last full month / Sales of the previous full month - 1
YTD - Year to Date - a period of time beginning the first day of the current calendar year up to the current date
MAT - Moving Annual Total - a period, being any 12 month period ending on the last week
MS - Market Share
Data Sources:
DSM: Sales
Palomars: TRPs
MI: Fact Digital Costs
MI Estimated Costs: TV costs